Celsion to Hold Annual Meeting: Shareholders May Participate by Telephone or Webcast

Business Wire, June 8, 2007

COLUMBIA, Md. -- CELSION CORPORATION (AMEX: CLN) will hold its annual meeting on Wednesday, June 13, 2007 at 10:00 a.m. ET, at the Four Points Sheraton Hotel at the BWI Airport in Baltimore, Maryland, with simultaneous webcast and telephone access.

To participate in the meeting by telephone, interested parties should dial 877-604-2080 (domestic) and 706-902-1383 (international), Passcode: 3137292# to register ten minutes before the meeting is scheduled to begin. The webcast can also be accessed at Celsion Corporation's website at www.celsion.com.

The audio will be archived for replay from Wednesday, June 13, 2007 at 11:00 a.m. until Thursday, June 15, 2007 at 12:00 noon. The replay can be accessed at 800-642-1687 (domestic) and 706-645-9291 (international). The audio will also be available on the Company's web site, http://www.celsion.com. The replay of the webcast will be available for 90 days. The archived webcast can be accessed in the same manner as the live webcast of the meeting.

About Celsion: Celsion is dedicated to the development and commercialization of oncology drugs including tumor-targeting treatments using focused heat energy in combination with heat activated drug delivery systems.

Celsion has research, license or commercialization agreements with leading institutions such as the National Institutes of Health, Duke University Medical Center, University of Hong Kong, Cleveland Clinic, North Shore Long Island Jewish Health System.

Celsion has also developed a microwave based system, the Prolieve Thermodilatation[R] system, for the treatment of benign prostatic hyperplasia which is marketed in the United States under an exclusive distribution agreement with Boston Scientific Corporation. For more information on Celsion, visit our website: http://www.celsion.com.

Celsion wishes to inform readers that forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials by others; possible acquisitions of other technologies, assets or businesses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.